334 related articles for article (PubMed ID: 32192503)
1. Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney.
Giugliano D; De Nicola L; Maiorino MI; Bellastella G; Garofalo C; Chiodini P; Ceriello A; Esposito K
Cardiovasc Diabetol; 2020 Mar; 19(1):35. PubMed ID: 32192503
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
Yamada T; Wakabayashi M; Bhalla A; Chopra N; Miyashita H; Mikami T; Ueyama H; Fujisaki T; Saigusa Y; Yamaji T; Azushima K; Urate S; Suzuki T; Abe E; Wakui H; Tamura K
Cardiovasc Diabetol; 2021 Jan; 20(1):14. PubMed ID: 33413348
[TBL] [Abstract][Full Text] [Related]
3. Are SGLT2 Inhibitors Ready for Prime Time for CKD?
Pecoits-Filho R; Perkovic V
Clin J Am Soc Nephrol; 2018 Feb; 13(2):318-320. PubMed ID: 28893920
[No Abstract] [Full Text] [Related]
4. Class effect for SGLT-2 inhibitors: a tale of 9 drugs.
Giugliano D; Esposito K
Cardiovasc Diabetol; 2019 Jul; 18(1):94. PubMed ID: 31337395
[TBL] [Abstract][Full Text] [Related]
5. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs.
Giugliano D; Longo M; Scappaticcio L; Bellastella G; Maiorino MI; Esposito K
Cardiovasc Diabetol; 2021 Dec; 20(1):236. PubMed ID: 34915880
[TBL] [Abstract][Full Text] [Related]
6. GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off.
Giugliano D; Scappaticcio L; Longo M; Bellastella G; Esposito K
Cardiovasc Diabetol; 2021 Oct; 20(1):205. PubMed ID: 34641876
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.
Tanaka A; Shimabukuro M; Okada Y; Sugimoto K; Kurozumi A; Torimoto K; Hirai H; Node K;
Cardiovasc Diabetol; 2020 Jun; 19(1):85. PubMed ID: 32534578
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of SGLT-2 inhibitors in older adults with diabetes: Systematic review with meta-analysis of cardiovascular outcome trials.
Giugliano D; Longo M; Maiorino MI; Bellastella G; Chiodini P; Solerte SB; Esposito K
Diabetes Res Clin Pract; 2020 Apr; 162():108114. PubMed ID: 32165164
[TBL] [Abstract][Full Text] [Related]
9. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
Woo V; Connelly K; Lin P; McFarlane P
Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
[No Abstract] [Full Text] [Related]
10. Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
Weir MR
Postgrad Med; 2019 Aug; 131(6):367-375. PubMed ID: 31132013
[TBL] [Abstract][Full Text] [Related]
11. [Outcome studies on SGLT-2 inhibitors].
Seufert J; Laubner K
Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
[TBL] [Abstract][Full Text] [Related]
12. Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials : Perspective on GLP-1 RA and SGLT-2i therapies.
Ludwig L; Darmon P; Guerci B
Cardiovasc Diabetol; 2020 May; 19(1):65. PubMed ID: 32404155
[TBL] [Abstract][Full Text] [Related]
13. [In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?].
Lanthier L; Huard G; Plourde MÉ; Cauchon M
Rev Med Interne; 2020 Jan; 41(1):67-68. PubMed ID: 31812446
[No Abstract] [Full Text] [Related]
14. SGLT2i: beyond the glucose-lowering effect.
Ni L; Yuan C; Chen G; Zhang C; Wu X
Cardiovasc Diabetol; 2020 Jun; 19(1):98. PubMed ID: 32590982
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
[TBL] [Abstract][Full Text] [Related]
16. Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?
Dardano A; Miccoli R; Bianchi C; Daniele G; Del Prato S
Diabetes Res Clin Pract; 2020 Apr; 162():108112. PubMed ID: 32198123
[TBL] [Abstract][Full Text] [Related]
17. Exploring the heterogeneity of the effects of SGLT-2 inhibitors in cardiovascular outcome trials.
Mannucci E; Dicembrini I; Nreu B; Monami M
Nutr Metab Cardiovasc Dis; 2020 Jan; 30(1):71-76. PubMed ID: 31757568
[TBL] [Abstract][Full Text] [Related]
18. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
19. Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease.
Tuttle KR; Cherney DZ;
Clin J Am Soc Nephrol; 2020 Feb; 15(2):285-288. PubMed ID: 31740570
[No Abstract] [Full Text] [Related]
20. Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes.
Giugliano D; Longo M; Scappaticcio L; Caruso P; Esposito K
Cardiovasc Diabetol; 2021 Jan; 20(1):17. PubMed ID: 33430860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
